Anton Gopka

Anton Gopka is a Managing Member at ATEM Capital with a primary focus on private investments. Before ATEM, Anton was managing a biotech venture capital fund — a US$760 million strategic partnership between Domain Associates and a sovereign wealth fund. Notable exits include $1.7 billion sale of Tobira Therapeutics at an unprecedented premium to its current market cap (up to 19x) and IPO of Atea Pharmaceuticals in 2020 at 30x valuation to the Series A investment back in 2014.

Before that, Anton held senior positions in M&A advisory at Barclays Capital, Sistema JSFC (LSE: SSA), and Dresdner Kleinwort. Previous board memberships include Marinus Pharmaceuticals (NASDAQ: MRNS), Regado Biosciences which merged into Tobira Therapeutics (NASDAQ: TBRA), and Miramar Labs (observer). Anton received a master's degree in international economics from the Moscow State University for International Affairs (MGIMO-University), an advanced corporate finance course diploma from INSEAD, and a Board Leadership certificate from Harvard Business School.

He is a member of the US National Association of Corporate Directors (NACD) and a member of the Review Committee of the National Cancer Institute (NCI). Anton enjoys life, passionate for classical music & contemporary art.